Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452424 · ClinicalTrials.gov registry record · Phase 1
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
A Phase 1 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT02452424 is a Phase 1 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 78 participants.
The verdict
NCT02452424, a Phase 1 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R). Pembrolizumab is designed to block the interaction between the receptor PD-1 and molecules that bind PD-1. In this study, PLX3397 and pembrolizumab are being given together in order to study their combined effects on patients' immune responses to their tumors. Tumor-specific immune responses have been shown to kill cancer cells and/or to stop tumors from growing. Part 1 of the study (dose-escalation phase) will establish the safest dose of PLX3397 to be given in combination with pembrolizumab. Part 2 of the study (expansion phase) will include an evaluation of efficacy of this combination in the following tumor types: * Advanced melanoma: prior anti-PD-1/PD-L1 therapy but never responded * Advanced melanoma: prior anti-PD-1/PD-L1 therapy and responded but later progressed as defined by irRECIST while on therapy * Non-small cell lung cancer * Ovarian cancer * Gastrointestinal Stromal Tumor (GIST) * Squamous cell cancer of the head and neck
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG PLX3397
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2015-07-02 |
| Est. Completion | 2018-10-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02452424
The ClinicalTrials.gov registry entry for NCT02452424 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02452424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02452424 about?
NCT02452424 is a clinical study titled "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors". The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R). Pembrolizumab is designed to block the interaction between the receptor PD-1 and molecules that bind PD-1. In this st...
What is the current status of trial NCT02452424?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2015-07-02. Estimated completion is 2018-10-12.
What interventions are being tested in trial NCT02452424?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), PLX3397 (DRUG).
Who is sponsoring clinical trial NCT02452424?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.